HealthInvest Partners AB Invests $824,000 in Ambrx Biopharma Inc. (NYSE:AMAM)

HealthInvest Partners AB purchased a new stake in shares of Ambrx Biopharma Inc. (NYSE:AMAM) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 57,847 shares of the company’s stock, valued at approximately $824,000. HealthInvest Partners AB owned approximately 0.09% of Ambrx Biopharma as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Alps Advisors Inc. boosted its holdings in Ambrx Biopharma by 12.2% in the third quarter. Alps Advisors Inc. now owns 45,531 shares of the company’s stock worth $524,000 after acquiring an additional 4,933 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Ambrx Biopharma in the 4th quarter worth about $104,000. Renaissance Technologies LLC grew its position in Ambrx Biopharma by 91.5% during the 1st quarter. Renaissance Technologies LLC now owns 22,600 shares of the company’s stock valued at $93,000 after purchasing an additional 10,800 shares during the last quarter. Innovis Asset Management LLC increased its stake in Ambrx Biopharma by 85.1% during the 3rd quarter. Innovis Asset Management LLC now owns 31,137 shares of the company’s stock valued at $358,000 after purchasing an additional 14,311 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Ambrx Biopharma in the first quarter worth about $156,000. 77.28% of the stock is owned by hedge funds and other institutional investors.

Ambrx Biopharma Price Performance

Shares of Ambrx Biopharma stock remained flat at $28.00 during trading hours on Tuesday. Ambrx Biopharma Inc. has a 12-month low of $6.55 and a 12-month high of $28.15. The firm’s fifty day moving average is $27.93 and its 200-day moving average is $19.71.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Ambrx Biopharma in a report on Friday, January 12th. JMP Securities restated a “market perform” rating on shares of Ambrx Biopharma in a research note on Wednesday, January 10th. B. Riley downgraded Ambrx Biopharma from a “buy” rating to a “neutral” rating and upped their price target for the company from $26.00 to $28.00 in a report on Tuesday, January 9th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $28.00 price objective on shares of Ambrx Biopharma in a report on Tuesday, January 16th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Ambrx Biopharma has a consensus rating of “Moderate Buy” and an average price target of $24.13.

Ambrx Biopharma Company Profile

Ambrx Biopharma Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2.